Your browser doesn't support javascript.
Trend of expansion of SARS-CoV-2 infection and COVID-19 burden in Gabon (Central Africa) in mid-2021, based on a serological survey.
Iroungou, Berthe A; Moussavou, Pamela Boundzanga; Elguero, Eric; Makran, Jamal; Bivigou-Mboumba, Berthold; Wora, Elise; Nzenze, Jean R; Niama, Fabien Roche; Aghokeng, Avelin F.
  • Iroungou BA; Unité Mixte de Recherche, Centre International de Recherches Médicales de Franceville et le Service de Santé Militaire, Libreville, Gabon.
  • Moussavou PB; Unité Mixte de Recherche, Centre International de Recherches Médicales de Franceville et le Service de Santé Militaire, Libreville, Gabon.
  • Elguero E; MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.
  • Makran J; MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.
  • Bivigou-Mboumba B; Unité Mixte de Recherche, Centre International de Recherches Médicales de Franceville et le Service de Santé Militaire, Libreville, Gabon.
  • Wora E; Unité Mixte de Recherche, Centre International de Recherches Médicales de Franceville et le Service de Santé Militaire, Libreville, Gabon.
  • Nzenze JR; Service de Médecine Interne, Hôpital d'Instruction des Armées Omar Bongo Ondimba, Libreville, Gabon.
  • Niama FR; National Laboratory of Public Health, Brazzaville, Republic of the Congo.
  • Aghokeng AF; Unité Mixte de Recherche, Centre International de Recherches Médicales de Franceville et le Service de Santé Militaire, Libreville, Gabon.
IJID Reg ; 5: 13-17, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2004138
ABSTRACT

Objective:

To estimate the seroprevalence of anti-SARS-CoV-2 antibodies in the general population in Gabon, Central Africa.

Methods:

From May to July 2021, a cross-sectional study involving participants recruited in the general population in three districts in Gabon was conducted. Eligible participants who provided written informed consent were tested for anti-SARS-CoV-2 antibodies using a simple rapid diagnostic assay.

Results:

Overall, 1609 participants were recruited, 1361 (84.6%) from urban sites and 248 (15.4%) from a rural area. The estimated overall seroprevalence was 13.1% (95% CI 11.4-14.8%). The risk of seropositivity increased with age, and the prevalence in the different age groups ranged from 12.9% (8.0-19.4%) in those aged 15-24 years to 23.3% (14.2-34.6%) in those ≥ 65 years old. A higher prevalence was found in the rural population (17.3%; 12.8-22.6%) compared with urban regions (12.3%; 10.6-14.1%). Being a woman was also associated with higher risk of infection (p < 0.001).

Conclusions:

This seroprevalence survey revealed a moderate seroprevalence in Gabon, illustrating a relatively low rate of circulation of the virus in the country and correlating with low numbers of confirmed cases and deaths reported to date.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: IJID Reg Year: 2022 Document Type: Article Affiliation country: J.ijregi.2022.08.006

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: IJID Reg Year: 2022 Document Type: Article Affiliation country: J.ijregi.2022.08.006